Controversial Avastin Spit and Ship Study to Help Triple Negative Breast Cancer Patients

EmaxHealth Health News

By Timothy Boyer for eMaxHealth.com

Undeterred by the U.S. Food and Drug Administration (FDA) removal of Avastin for breast cancer, makers of the drug are now seeking breast cancer patients who have previously used Avastin to provide saliva samples in a spit and ship study titled “The InVite Study” to determine if there is a subset of women with breast cancer—such as those diagnosed with triple negative breast cancer—who may still benefit from Avastin.

Learn more.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco